Fight Colorectal Cancer shared a post on LinkedIn:
“More time. Better outcomes.
The BREAKWATER trial offers new hope for patients with BRAF V600E–mutant metastatic colorectal cancer. Researchers found that the combination of encorafenib + cetuximab + mFOLFOX6 led to improved results—and may become a new first-line treatment option.
This is personalized care in action.
If you’re living with metastatic CRC, ask your doctor about biomarker testing. Knowing your biomarkers can help guide your treatment plan.
Swipe to learn about more promising research.”
